April 6, 2024Molecular Therapy67 citationsOpen Access

Engineering allorejection-resistant CAR-NKT cells from hematopoietic stem cells for off-the-shelf cancer immunotherapy

YLYan-Ruide LiUniversity of California, Los Angeles YZYang ZhouUniversity of California, Los Angeles JYJiaji YuUniversity of California, Los Angeles

Key Points

Key points are not available for this paper at this time.

Abstract

The clinical potential of current FDA-approved chimeric antigen receptor (CAR)-engineered T (CAR-T) cell therapy is encumbered by its autologous nature, which presents notable challenges related to manufacturing complexities, heightened costs, and limitations in patient selection. Therefore, there is a growing demand for off-the-shelf universal cell therapies. In this study, we have generated universal CAR-engineered NKT (

AI से पूछें

Bookmark

View Full Paper